Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Targeting FLT3 in Patients with Relapsed/Refractory AML

July 22nd 2019

Recent Data on the Treatment of Older Patients With AML

July 22nd 2019

Management of Adverse Events in Older Patients With AML

July 22nd 2019

Role of Hypomethylating Agents in AML

July 22nd 2019

Treatment of AML With Myelodysplasia-Related Changes

July 22nd 2019

Role of Maintenance Therapy in AML

July 22nd 2019

Consolidation Strategies in AML

July 22nd 2019

Treatment Strategies and Patient Specific Factors in AML

July 22nd 2019

MRD Assessment and its Clinical Implications in AML

July 22nd 2019

Prognostic Significance of MRD in AML

July 22nd 2019

Therapeutic Approaches Based on Mutations in AML

July 22nd 2019

Best Practices for NGS Testing in AML

July 22nd 2019

Genetic Alterations in Acute Myeloid Leukemia

July 22nd 2019

Dr. Redner on the Potency of Gilteritinib in AML

July 19th 2019

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the potency of gilteritinib (Xospata) in acute myeloid leukemia (AML).

Practical Perspectives on the Diagnosis and Treatment of Hairy Cell Leukemia

July 13th 2019

Gary J. Schiller, MD, discusses the challenges with treating patients with hairy cell leukemia and some emerging therapies that could impact clinical practice.

Advances in the Treatment of Relapsed or Refractory Hairy Cell Leukemia

July 12th 2019

After decades of quiescence, the therapeutic landscape of hairy cell leukemia is undergoing rapid evolution.

Research Abounds Across Lymphomas, But More Work Remains

July 11th 2019

Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.

Devimistat Could Have Practice-Changing Potential in Burkitt Lymphoma

July 11th 2019

Ariela Noy, MD, discusses a phase II trial of devimistat in Burkitt lymphoma and other lymphomas, and describes the unique mechanism of action of the agent.

Hairy Cell Leukemia: A Review of Epidemiology and Disease Presentation

July 11th 2019

Despite the significant progress that has been made regarding the incidence, risk factors, and symptoms of hairy cell leukemia, diagnosis remains a challenge, due in part to the low incidence of the disease.

A Rare but Treatable Disease: Therapeutic Considerations for Hairy Cell Leukemia

July 11th 2019

Martin S. Tallman, MD, discusses the biology, presentation, and available therapeutic options in hairy cell leukemia.